Metabolic Effects of Angiotensin-(1-7)
Eligible age
18–60 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies. It is unclear if this peptide contributes to the regulation of metabolism in humans. The investigators will test if angiotensin-(1-7) infusion can improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with obesity and insulin resistance. The investigators will also examine for changes in blood pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.
Sponsor: Vanderbilt University
You may qualify if…
- ✓ Males and females of all races between 18 and 60 years of age
- ✓ Obesity defined as body mass index between 30-40 kg/m2
- ✓ Insulin resistance defined as homeostasis model assessment 2 insulin resistance (HOMA2-IR) score \>2.2
- ✓ Hypertension defined by two or more properly measured seated blood pressure readings \>130/85 mmHg, or by use of anti-hypertensive medications. This blood pressure cutoff will allow us to include subjects with pre-hypertension.
- ✓ Able and willing to provide informed consent
You may not qualify if…
- ✕ Pregnancy or breast-feeding
- ✕ Current smokers or history of heavy smoking (\>2 packs/day)
- ✕ History of alcohol or drug abuse
- ✕ Morbid obesity (BMI \> 40 kg/m2)
- ✕ Previous allergic reaction to study medications
- ✕ Evidence of type I or type II diabetes (i.e. fasting glucose \>126 mg/dl, use of anti-diabetic medications)
- ✕ Cardiovascular disease other than hypertension such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy
- ✕ History of serious cerebrovascular disease such as cerebral hemorrhage, stroke, or transient ischemic attack
Where it's recruiting
Nashville
Source: ClinicalTrials.gov · NCT02646475 · last updated 2026-05-22